Autopsy report · NCT04342117

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

“Strategy Change”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

SecuraBio

Sponsor type

Industry

Conditions

Lymphoma, Small Lymphocytic; Lymphoma; Lymphoma, Non-Hodgkin; Chronic Lymphocytic Leukemia; Follicular Lymphoma

Interventions

duvelisib; PI3K inhibitor

Participants

2

Sites

11

Countries

United States

Trials that died the same way

• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (96% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (84% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (80% match in meaning)
• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (75% match in meaning)
• Efficacy and Safety of Tiradentes Association in the Treatment of Acute Pain
  “Strategy review” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.